Lymphoma

Latest News

Phase 3 data show that nivolumab/AVD may also reduce long-term toxicities vs brentuximab vedotin/AVD in advanced Hodgkin lymphoma.
Nivolumab Combo Improves PFS in Stage III/IV Advanced Hodgkin Lymphoma

October 17th 2024

Phase 3 data show that nivolumab/AVD may also reduce long-term toxicities vs brentuximab vedotin/AVD in advanced Hodgkin lymphoma.

The FDA has set a Prescription Drug User Fee Act date in the first quarter of 2025 for the potential approval of acalabrutinib in previously untreated MCL.
Acalabrutinib Earns FDA Priority Review in Untreated Mantle Cell Lymphoma

October 3rd 2024

Reconsidering REMS Mandate May Improve CAR T-Cell Therapy Accessibility
Reconsidering REMS Mandate May Improve CAR T-Cell Therapy Accessibility

September 23rd 2024

Complete responses were observed in a small cohort of patients with DLBCL who have previously received autologous CAR T-cell therapy.
Azer-Cel Achieves Complete Responses in Relapsed/Refractory DLBCL

September 18th 2024

Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.
Valemetostat Shows Meaningful Benefit in Peripheral T-Cell Lymphoma

September 10th 2024

Latest CME Events & Activities

More News